Angiogenesis in Diabetic Nephropathy

Seminars in Nephrology

Volumn 27, Issue 2, 2007, Pages 161-171

  Zent, Roy ^a   Pozzi, Ambra ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; diabetes; endothelial cells; kidney; therapy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; ENDOSTATIN; GENE PRODUCT; PYRIDOXAMINE; TUMSTATIN; VALSARTAN; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL INJURY; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; ENDOTHELIAL CELLS; HUMANS; KIDNEY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34147168769     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.01.007     Document Type: Article

References (77)

1. Pandya N.M., Dhalla N.S., and Santani D.D. Angiogenesis-a new target for future therapy. Vascul Pharmacol 44 (2006) 265-274
2. Roy H., Bhardwaj S., and Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 580 (2006) 2879-2887
3. Olsson A.K., Dimberg A., Kreuger J., et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7 (2006) 359-371
4. Eklund L., and Olsen B.R. Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. Exp Cell Res 312 (2006) 630-641
5. Thurston G., Rudge J.S., Ioffe E., et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6 (2000) 460-463
6. Thurston G., Suri C., Smith K., et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286 (1999) 2511-2514
7. Scharpfenecker M., Fiedler U., Reiss Y., et al. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 118 (2005) 771-780
8. Roviezzo F., Tsigkos S., Kotanidou A., et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 314 (2005) 738-744
9. Benest A.V., Salmon A.H., Wang W., et al. VEGF and angiopoietin-1 stimulate different angiogenic phenotypes that combine to enhance functional neovascularization in adult tissue. Microcirculation 13 (2006) 423-437
10. Zhang L., Yang N., Park J.W., et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63 (2003) 3403-3412
11. Sato Y. Update on endogenous inhibitors of angiogenesis. Endothelium 13 (2006) 147-155
12. Sudhakar A., Nyberg P., Keshamouni V.G., et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 115 (2005) 2801-2810
13. Zent R., and Pozzi A. Extracellular matrix and the development of disease: the role of its component in cancer progression. Adv Dev Biol 15 (2005) 203-228
14. Volpert O.V., Zaichuk T., Zhou W., et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 8 (2002) 349-357
15. Steele F.R., Chader G.J., Johnson L.V., et al. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A 90 (1993) 1526-1530
16. Dawson D.W., Volpert O.V., Gillis P., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
17. Zhang S.X., Wang J.J., Gao G., et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37 (2006) 1-12
18. Schrijvers B.F., De Vriese A.S., and Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25 (2004) 971-1010
19. van Dijk C., and Berl T. Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord 5 (2004) 237-248
20. Zent R., Yan X., Su Y., et al. Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Kidney Int 70 (2006) 460-470
21. Susztak K., Raff A.C., Schiffer M., et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55 (2006) 225-233
22. Iglesias-De La Cruz M.C., Ruiz-Torres P., Alcami J., et al. Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells. Kidney Int 59 (2001) 87-95
23. Park S.K., Kim J., Seomun Y., et al. Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 284 (2001) 966-971
24. Forbes J.M., Cooper M.E., Oldfield M.D., et al. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 14 (2003) S254-S258
25. Nagase M., Shibata S., Yoshida S., et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47 (2006) 1084-1093
26. Osterby R., Asplund J., Bangstad H.J., et al. Neovascularization at the vascular pole region in diabetic glomerulopathy. Nephrol Dial Transplant 14 (1999) 348-352
27. Nyengaard J.R., and Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia 36 (1993) 189-194
28. Guo M., Ricardo S.D., Deane J.A., et al. A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat 207 (2005) 813-821
29. Kanesaki Y., Suzuki D., Uehara G., et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 45 (2005) 288-294
30. Wang J.J., Zhang S.X., Lu K., et al. Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. Diabetes 54 (2005) 243-250
31. Kim N.H., Oh J.H., Seo J.A., et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 67 (2005) 167-177
32. Iglesias-de la Cruz M.C., Ziyadeh F.N., Isono M., et al. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 62 (2002) 901-913
33. Hohenstein B., Hausknecht B., Boehmer K., et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int 69 (2006) 1654-1661
34. Bortoloso E., Del Prete D., Dalla Vestra M., et al. Quantitative and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol 150 (2004) 799-807
35. Eremina V., and Quaggin S.E. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13 (2004) 9-15
36. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111 (2003) 707-716
37. Uchida K., Uchida S., Nitta K., et al. Glomerular endothelial cells in culture express and secrete vascular endothelial growth factor. Am J Physiol 266 (1994) F81-F88
38. Lee K.S., Kim S.R., Park S.J., et al. Hydrogen peroxide induces vascular permeability via regulation of vascular endothelial growth factor. Am J Respir Cell Mol Biol 35 (2006) 190-197
39. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 277 (2002) 20309-20315
40. Woolf A.S., and Yuan H.T. Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr Nephrol 16 (2001) 177-184
41. Satchell S.C., Harper S.J., Tooke J.E., et al. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 13 (2002) 544-550
42. Satchell S.C., Anderson K.L., and Mathieson P.W. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15 (2004) 566-574
43. Yamamoto Y., Maeshima Y., Kitayama H., et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53 (2004) 1831-1840
44. Ichinose K., Maeshima Y., Yamamoto Y., et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 54 (2005) 2891-2903
45. Singh A.K., Gudehithlu K.P., Pegoraro A.A., et al. Vascular factors altered in glucose-treated mesangial cells and diabetic glomeruli. Changes in vascular factors impair endothelial cell growth and matrix. Lab Invest 84 (2004) 597-606
46. Spranger J., Osterhoff M., Reimann M., et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 50 (2001) 2641-2645
47. Yamagishi S., Matsui T., and Inoue H. Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells. Drugs Exp Clin Res 31 (2005) 227-232
48. Wang J.J., Zhang S.X., Mott R., et al. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. Diabetes 55 (2006) 1678-1685
49. Kang Y.S., Park Y.G., Kim B.K., et al. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol 36 (2006) 377-388
50. Uemura H., Nakaigawa N., Ishiguro H., et al. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 5 (2005) 307-323
51. Yoshiji H., Noguchi R., Kuriyama S., et al. Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats. Anticancer Res 25 (2005) 3335-3340
52. Yoshiji H., Kuriyama S., Noguchi R., et al. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets 4 (2004) 555-567
53. Yoshiji H., Kuriyama S., Kawata M., et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7 (2001) 1073-1078
54. Duh E., and Aiello L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48 (1999) 1899-1906
55. Aiello L.P., and Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77 (2000) S113-S119
56. Satchell S.C., and Mathieson P.W. Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology. J Nephrol 16 (2003) 168-178
57. de Vriese A.S., Tilton R.G., Elger M., et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12 (2001) 993-1000
58. Flyvbjerg A., Dagnaes-Hansen F., De Vriese A.S., et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51 (2002) 3090-3094
59. Schrijvers B.F., Flyvbjerg A., Tilton R.G., et al. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 21 (2006) 324-329
60. Schrijvers B.F., De Vriese A.S., Tilton R.G., et al. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes. Horm Metab Res 37 (2005) 21-25
61. Gupta K., and Zhang J. Angiogenesis: a curse or cure?. Postgrad Med J 81 (2005) 236-242
62. Zhang S.X., Wang J.J., Lu K., et al. Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol 17 (2006) 475-486
63. Griscelli F., Li H., Bennaceur-Griscelli A., et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U S A 95 (1998) 6367-6372
64. Sima J., Zhang S.X., Shao C., et al. The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett 564 (2004) 19-23
65. Chung A.W., Hsiang Y.N., Matzke L.A., et al. Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res 99 (2006) 140-148
66. Chen S., Lee J.S., Iglesias-de la Cruz M.C., et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 20 (2005) 1320-1328
67. Goldin A., Beckman J.A., Schmidt A.M., et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
68. Wautier M.P., Chappey O., Corda S., et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 280 (2001) E685-E694
69. Pala L., Cresci B., Manuelli C., et al. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: biological effects and advanced glycosylation end products modulation. Microvasc Res 70 (2005) 179-188
70. Yamagishi S., Yonekura H., Yamamoto Y., et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 272 (1997) 8723-8730
71. Flyvbjerg A., Denner L., Schrijvers B.F., et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53 (2004) 166-172
72. Jensen L.J., Denner L., Schrijvers B.F., et al. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J Endocrinol 188 (2006) 493-501
73. Kelly D.J., Gilbert R.E., Cox A.J., et al. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 12 (2001) 2098-2107
74. Booth A.A., Khalifah R.G., Todd P., et al. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272 (1997) 5430-5437
75. Degenhardt T.P., Alderson N.L., Arrington D.D., et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61 (2002) 939-950
76. Zheng F., Zeng Y.J., Plati A.R., et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 70 (2006) 507-514
77. Pozzi A., Moberg P.E., Miles L.A., et al. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 97 (2000) 2202-2207